Crunching the numbers for APLS... Refresh in a moment for the full analysis.
Apellis Pharmaceuticals, Inc. (APLS)
Healthcare
healthy
$40.79
Updated: 2026-04-12
63
TradeApes Score
add
Financial Strength
65
Healthy
Operating Trend
80
Strong
Valuation
50
Mixed
Capital Allocation
50
Mixed
Risk
70
Healthy
Key Findings
+
Net cash position — more cash on hand than total debt
−
Piotroski F-Score 0–3 — multiple financial weakness signals
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Create Free Account
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.